GMR Solutions’ 2026 Q2 Earnings Call: ACA Subsidy and IDR Impact Estimates Diverge

Date of Call: Aug 13, 2026

Financials Results

• Revenue: $1.49 billion, up 3.3% year-over-year
• EPS: Net loss of $28.3 million compared to net income of $80.8 million in the prior year period
• Operating Margin: Adjusted EBITDA margin of 19.1%, down from prior year due to lower changes in estimates related to No Surprises Act claims

Guidance:

• Revenue expected in the range of $5.89 billion to $6.18 billion for the full year.
• Adjusted EBITDA expected in the range of $1.135 billion to $1.195 billion for the full year.
• Total cash used for CapEx and aircraft financing expected between 5.1% and 5.3% of total revenue.
• Guidance assumes continued momentum in transport rates and volumes, stable payer mix reflecting elimination of ACA exchange subsidies, and ongoing impact of prolonged Iran conflict.

Business Commentary:

Financial Performance and Revenue Growth:

• GMR Solutions reported Q2 2026 revenue of $1.49 billion, representing a 3.3% year-over-year increase.
• The growth was driven by strong underlying revenue and operating performance, with a focus on same-market revenue growth, cross-selling, and disciplined cost management.

Operational Performance and Patient Encounters:

• The company completed nearly 1.4 million patient encounters in Q2 2026, including over 1.3 million ground medical services and over 36,000 air medical services.
• This was attributed to continued optimization of clinical and operational platforms and an unwavering focus on service to communities.

Impact of External Factors on Financials:

• Adjusted EBITDA decreased by 11.8% year-over-year to $285 million, with a margin of 19.1%.
• The decline was due to the expiration of Affordable Care Act exchange subsidies and lower changes in estimates related to No Surprises Act claims from earlier dates of service.

Growth and Market Expansion:

• Same market revenue increased by 3.8% year-over-year, and new market revenue was $21.3 million.
• Growth was driven by the opening of new 911 systems and air bases, as well as the execution of new agreements.

Efficiency and Innovation Initiatives:

• The company saw a 50% year-over-year increase in 911 Nurse Navigation calls, navigating nearly 29,000 calls in Q2 2026.
• This initiative improved resource utilization and patient outcomes, showcasing the value of integrating clinical care with operational decision-making.

Sentiment Analysis:

Overall Tone: Positive

• CEO stated 'We are excited to report strong financial and operational results in the second quarter of 2026 that are in line with our expectations' and 'The second quarter reinforces our confidence in GMR strategy and execution. Underlying performance was strong.' Management highlighted strong patient encounters, revenue growth, and operational efficiencies despite headwinds.

Q&A:

• Question from Scott Fidel (Goldman Sachs): Could you provide more context on IDR dynamics and trends year-to-date?
  Response: Changes in estimates related to No Surprises Act claims were about $79 million in Q2 2025 vs. $5 million in Q2 2026, indicating improved ability to dial in estimates, with future expectations around zero plus or minus five million.

• Question from Scott Fidel (Goldman Sachs): Could you walk us through payer mix dynamics and the impact from lower commercial payer mix?
  Response: The payer mix shift is largely driven by the expiration of ACA exchange subsidies and the year-over-year comparison with No Surprises Act benefits, with consistent impact observed since April.

• Question from Elizabeth Anderson (Evercore ISI): Can you elaborate on the improved capture rate?
  Response: Improved capture rate was driven by better weather, technology (like Transport.Net), and investments in IFR capabilities to mitigate weather impacts, leading to higher availability to capture demand.

• Question from Elizabeth Anderson (Evercore ISI): Can you parse out the specific FIFA World Cup revenue?
  Response: FIFA World Cup revenue was a couple million dollars, a very low revenue piece, not all of which flows through to earnings.

• Question from Benjamin Rossi (JPMorgan): What were the new business wins and their potential contributions?
  Response: Wins included new 911 systems on ground and air in adjacent markets, providing operational synergies and integrated market opportunities, with potential for more similar wins in the rest of the year.

• Question from A.J. Rice (UBS): What is the rollout progress and target for 911 Nurse Navigation?
  Response: Currently covers 29 communities (~20 million lives) out of a potential 200 million; aiming for 100 million covered lives in 5 years, with three growth channels: existing footprint, rural health transformation, and large metro models.

• Question from A.J. Rice (UBS): What is the target leverage and interest in potential M&A?
  Response: Target leverage is 3.0x by end of 2027; M&A pipeline includes about 15 targets, with focus on adjacent markets and evaluating whether to buy or win business, pending market conditions.

• Question from Joanna Gajek (Bank of America): How will the new IDR regulation impact your process, and what are your thoughts on potential changes?
  Response: The new IDR rules provided slight tailwind ($1-2M annually) and cleaned up the process; prefers in-network deals for ease and faster cash, but will continue to beat plans in IDR if necessary, with concerns about plan behavior.

• Question from Joanna Gajek (Bank of America): Should we assume a similar $16M EBITDA headwind per quarter from subsidy expiration?
  Response: Yes, the $15-16M per quarter impact from ACA subsidy expiration is baked into forward guidance for both revenue and EBITDA.

• Question from Andrew Mok (Barclays): What drove the meaningful increase in air bases, and what is the expected pace?
  Response: Air base increase was 3-4 in Q2, driven by aircraft deliveries tied to contracts; additional high single-digit bases planned for remainder of the year, slightly delayed due to supplier timing, but overall growth is expected.

• Question from Andrew Mok (Barclays): What percentage of contracts are in-network, and what progress is being made?
  Response: In-network rate hovers around 69-70% for air; prefers in-network at a discount due to easier process and faster cash, with ongoing efforts to bring more payers in-network.

• Question from Craig Hettenbach (Morgan Stanley): What are the volume expectations for the implied second half guidance?
  Response: Second half expectations are based on planned new base growth and starts, factoring in weather and other market variables; forecast remains as outlined in guidance.

• Question from Craig Hettenbach (Morgan Stanley): What are the key operating efficiency drivers and technology's role in expanding margins?
  Response: Efficiencies driven by labor matching to volume, back-office improvements, AI initiatives, procurement focus, and leveraging scale for best practices and standardization across the platform, all aimed at optimizing patient care time.

• Question from Luis (Citigroup): What is driving the expected margin compression in the back half of the year?
  Response: Margin compression driven by ongoing impact of ACA subsidy expiration (not fully felt in H1), prolonged Iran conflict costs ($10M+/quarter fuel impact), and associated increases in airfare, shipping, and fuel surcharges across the P&L.

Contradiction Point 1

Financial Impact of ACA Subsidy Expiration

It involves a significant change in the quantified quarterly financial impact, which is a material metric for investors to assess company performance and future guidance.

Joanna Gajek (Bank of America) - Joanna Gajek (Bank of America)

2026Q2: The subsidy expiration impact is a ~$15-16 million quarterly headwind on both revenue and EBITDA... - [Brian Tierney](CFO)

How does the new IDR regulation and potential changes suggested by health plans impact the process, and could you clarify the subsidy expiration headwind? - Benjamin Rossi (JPMorgan Chase & Co, Research Division)

2026Q1: For 2026 guidance, an estimated total impact of $25–$30 million from OBBA and ACA subsidy expiration over the next 9 months has been factored in. - [Nicola Loporcaro](CEO), [Brian Tierney](CFO)

Contradiction Point 2

Nature of IDR Regulatory Impact

It reflects a shift in characterizing the financial significance of a new regulation, moving from "not expected to be material" to specifying a concrete, albeit small, tailwind. This affects the perceived stability and predictability of the regulatory environment.

Joanna Gajek (Bank of America) - Joanna Gajek (Bank of America)

2026Q2: The new IDR regulations provided slight tailwinds with lower fees, estimated at $1-2 million annually, but had minimal overall impact. - [Nick Loporcaro](CEO)

How does the new IDR regulation and potential health plan changes impact the process, and what is the effect of the subsidy expiration headwind? - Andrew Mok (Barclays Bank PLC, Research Division)

2026Q1: The final IDR rule is viewed as positive for processing efficiency, though the financial impact is not expected to be material. - [Nicola Loporcaro](CEO), [Brian Tierney](CFO)